None
Quote | Mandatum Pankki Oyj (OTCMKTS:MDNAF)
Last: | $1.37 |
---|---|
Change Percent: | -3.25% |
Open: | $1.27 |
Close: | $1.37 |
High: | $1.56 |
Low: | $1.25 |
Volume: | 220,125 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Mandatum Pankki Oyj (OTCMKTS:MDNAF)
TORONTO and HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that two posters wi...
2024-02-14 07:56:58 ET More on Medicenna Therapeutics Seeking Alpha’s Quant Rating on Medicenna Therapeutics Historical earnings data for Medicenna Therapeutics Financial information for Medicenna Therapeutics Read the full article on Seeking Alpha ...
Message Board Posts | Mandatum Pankki Oyj (OTCMKTS:MDNAF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Mandatum Pankki Oyj Company Name:
MDNAF Stock Symbol:
OTCMKTS Market:
TORONTO and HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that two posters wi...
With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose phase-2 eligible patients (N=13) that failed checkpoint inhibitor therapies, while maintaining an acceptable safety profile Tumor shrinkage was al...
The ABILITY-1 Study is evaluating MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA ® (pembrolizumab) for treatment of patients with advanced solid tumors MDNA11 continues to demonstrate encouraging single-agent activity from the mono...